[go: up one dir, main page]

PE20191495A1 - Piridonamidas como moduladores de canales de sodio - Google Patents

Piridonamidas como moduladores de canales de sodio

Info

Publication number
PE20191495A1
PE20191495A1 PE2019001687A PE2019001687A PE20191495A1 PE 20191495 A1 PE20191495 A1 PE 20191495A1 PE 2019001687 A PE2019001687 A PE 2019001687A PE 2019001687 A PE2019001687 A PE 2019001687A PE 20191495 A1 PE20191495 A1 PE 20191495A1
Authority
PE
Peru
Prior art keywords
pyridonamides
sodium channel
optionally substituted
channel modulators
halogen
Prior art date
Application number
PE2019001687A
Other languages
English (en)
Inventor
Sara Sabina Hadida-Ruah
Corey Anderson
Vijayalaksmi Arumugam
Iuliana Luci Asgian
Brian Richard Bear
Andreas P Termin
Jr James Philip Johnson
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE20191495A1 publication Critical patent/PE20191495A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ink Jet (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Referido a un proceso para preparar un compuesto de formula I, o su sal farmaceuticamente aceptable, en donde R1, R2, R3 y R4 son independientemente H, halogeno, CN, alquilo C1-C6 opcionalmente sustituidos, entre otros; R5, R5', R6, R6' y R7 son independientemente H, halogeno, CN, o -X-Rx; X es un enlace o alquilo C1-C6 opcionalmente sustituido; Rx esta ausente, es H o cicloalifatico C3-C8 opcionalmente sustituido. Estos compuestos son piridonamidas moduladores de canales de sodio. Tambien se refiere su uso en el tratamiento de diversos trastornos, incluyendo dolor.
PE2019001687A 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio PE20191495A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759059P 2013-01-31 2013-01-31
PCT/US2014/013652 WO2014120808A1 (en) 2013-01-31 2014-01-29 Pyridone amides as modulators of sodium channels

Publications (1)

Publication Number Publication Date
PE20191495A1 true PE20191495A1 (es) 2019-10-21

Family

ID=50073531

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001572A PE20151781A1 (es) 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio
PE2019001687A PE20191495A1 (es) 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015001572A PE20151781A1 (es) 2013-01-31 2014-01-29 Piridonamidas como moduladores de canales de sodio

Country Status (34)

Country Link
US (6) US9051270B2 (es)
EP (3) EP3865475A1 (es)
JP (4) JP6389194B2 (es)
KR (2) KR102227592B1 (es)
CN (2) CN105026373B (es)
AP (1) AP2015008633A0 (es)
AR (1) AR094667A1 (es)
AU (3) AU2014212509B2 (es)
BR (1) BR112015018289A2 (es)
CA (1) CA2898866C (es)
CL (1) CL2015002147A1 (es)
CY (1) CY1119163T1 (es)
DK (2) DK2953931T3 (es)
ES (2) ES2626555T3 (es)
GE (2) GEP20207177B (es)
HR (2) HRP20170787T1 (es)
HU (2) HUE033370T2 (es)
IL (2) IL269964B1 (es)
LT (2) LT3239134T (es)
MX (2) MX383688B (es)
NZ (2) NZ710270A (es)
PE (2) PE20151781A1 (es)
PH (1) PH12015501661B1 (es)
PL (2) PL3239134T3 (es)
PT (2) PT3239134T (es)
RS (2) RS56015B1 (es)
RU (1) RU2662223C2 (es)
SG (2) SG10201706206PA (es)
SI (2) SI3239134T1 (es)
SM (2) SMT202100030T1 (es)
TW (2) TWI714967B (es)
UA (1) UA120589C2 (es)
UY (1) UY35288A (es)
WO (1) WO2014120808A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010271A2 (pt) 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
TW201400446A (zh) 2012-05-22 2014-01-01 Genentech Inc Ｎ－取代之苯甲醯胺及其使用方法
CA2878478A1 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
NZ710111A (en) 2013-01-31 2020-08-28 Vertex Pharma Quinoline and quinoxaline amides as modulators of sodium channels
EP3865475A1 (en) 2013-01-31 2021-08-18 Vertex Pharmaceuticals Incorporated Process for preparing pyridone amides which are modulators of sodium channels and intermediate compounds used therein
CN105263490B (zh) 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
CA2918365C (en) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
AP2016009287A0 (en) 2013-12-13 2016-06-30 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
KR20180067561A (ko) 2015-09-28 2018-06-20 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
WO2017140728A1 (en) 2016-02-15 2017-08-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Taf1 inhibitors for the therapy of cancer
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
CR20190236A (es) 2016-10-17 2019-09-09 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CA3063901A1 (en) * 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CR20200064A (es) 2017-07-11 2020-08-03 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
CA3091012A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
GEP20237568B (en) 2018-11-02 2023-11-27 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EP3907218A4 (en) * 2019-01-04 2022-09-21 Jiangsu Hengrui Medicine Co., Ltd. 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, METHOD FOR PREPARATION AND MEDICAL USE
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020151728A1 (zh) * 2019-01-25 2020-07-30 江苏恒瑞医药股份有限公司 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
KR20210131357A (ko) * 2019-02-20 2021-11-02 지앙수 헨그루이 메디슨 컴퍼니 리미티드 6-옥소-1,6-디하이드로피리다진 프로드러그 유도체, 이의 제조 방법, 및 의약에서의 이의 응용
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) * 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
TW202115038A (zh) * 2019-08-19 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用
PE20221515A1 (es) * 2019-09-12 2022-10-04 Shanghai Jemincare Pharmaceuticals Co Ltd Oxinitruro de piridina, metodo para su preparacion y uso de este
JOP20220130A1 (ar) 2019-12-06 2023-01-30 Vertex Pharma مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
CN113045487B (zh) * 2019-12-27 2025-01-17 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
IL299180A (en) 2020-06-17 2023-02-01 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114031518B (zh) 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
JP7522943B2 (ja) 2021-05-07 2024-07-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害薬としてのシクロアルキル ３－オキソピペラジンカルボキサミド類及びシクロヘテロアルキル ３－オキソピペラジンカルボキサミド類
CA3222197A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
WO2022256622A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
WO2023160509A1 (zh) * 2022-02-25 2023-08-31 中国科学院上海药物研究所 脒类衍生化合物及其制备方法和用途
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN119522214A (zh) 2022-04-22 2025-02-25 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN116947713A (zh) * 2022-04-25 2023-10-27 中国科学院上海药物研究所 并环类化合物及其应用
KR20250006217A (ko) 2022-04-25 2025-01-10 사이트원 테라퓨틱스, 인코포레이티드 통증 치료를 위한 Naν1.8의 바이사이클릭 헤테로사이클릭 아미드 억제제
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH598252A5 (es) * 1974-01-04 1978-04-28 Hoffmann La Roche
GB1447583A (en) * 1974-02-04 1976-08-25 Ici Ltd Xanthene derivatives
US4086350A (en) * 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
GB1543964A (en) * 1976-04-08 1979-04-11 Ici Ltd Method of antagonising herbicides on soyabean and cotton
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JP3285391B2 (ja) * 1992-09-01 2002-05-27 日本化学工業株式会社 ２−フェノキシ安息香酸の製造法
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU7712000A (en) 1999-09-24 2001-04-24 Johns Hopkins University School Of Medicine, The Methods for identifying an agent that corrects defective protein folding
JP2003034671A (ja) * 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
PT1490064E (pt) 2002-02-14 2009-12-28 Pharmacia Corp Piridinonas substituídas como moduladores de p38 map-quinase
TW200524888A (en) * 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
CN1867551B (zh) * 2003-09-03 2013-09-11 拉夸里亚创药株式会社 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物
WO2006011050A2 (en) 2004-07-23 2006-02-02 Pfizer Limited Pyridine derivatives
MX2007015726A (es) 2005-06-09 2008-03-04 Vertex Pharma Derivados de indano como moduladores de canales ionicos.
WO2007030618A2 (en) 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
ES2383090T3 (es) 2005-10-12 2012-06-18 Vertex Pharmaceuticals, Inc. Derivados de bifenilo como moduladores de los canales iónicos dependientes de voltaje
RU2470012C2 (ru) 2006-04-11 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Композиции, полезные в качестве ингибиторов потенциалзависимых натриевых каналов
EP2183241B1 (en) 2007-05-03 2012-12-19 Pfizer Limited 2-pyridine carboxamide derivatives as sodium channel modulators
AU2008256937A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
NZ584519A (en) * 2007-10-11 2012-07-27 Vertex Pharma Aryl amides useful as inhibitors of voltage-gated sodium channels
EP2227453B1 (en) * 2007-10-11 2016-03-09 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
AU2008310661A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
US8461185B2 (en) * 2007-10-31 2013-06-11 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
CA2745952A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
KR101605061B1 (ko) * 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
CA2791281A1 (en) * 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US8999967B2 (en) * 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
CN106008504A (zh) 2011-02-02 2016-10-12 沃泰克斯药物股份有限公司 作为离子通道调节剂的吡咯并吡嗪-螺环哌啶酰胺
EP2675810A1 (en) * 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
AU2012229187B2 (en) 2011-03-14 2016-11-10 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
MX342324B (es) * 2011-03-29 2016-09-23 Sanofi Sa Formulaciones de otamixaban con estabilidad mejorada.
WO2013021535A1 (ja) 2011-08-10 2013-02-14 三菱電機株式会社 誘導加熱調理器及びそのプログラム
CN102584774B (zh) * 2011-12-22 2014-08-06 合肥工业大学 一种呫吨酮类衍生物及其用途
CA2863892C (en) 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CN102659628B (zh) * 2012-04-26 2014-07-02 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
EP3865475A1 (en) 2013-01-31 2021-08-18 Vertex Pharmaceuticals Incorporated Process for preparing pyridone amides which are modulators of sodium channels and intermediate compounds used therein
NZ710111A (en) 2013-01-31 2020-08-28 Vertex Pharma Quinoline and quinoxaline amides as modulators of sodium channels
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
MX359882B (es) 2013-01-31 2018-10-15 Vertex Pharma Amidas como moduladores de canales de sodio.
CA2918365C (en) 2013-07-19 2021-09-07 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
AP2016009287A0 (en) 2013-12-13 2016-06-30 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
CR20200064A (es) 2017-07-11 2020-08-03 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
CA3091012A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain

Also Published As

Publication number Publication date
RS56015B1 (sr) 2017-09-29
US10738009B2 (en) 2020-08-11
GEP20207177B (en) 2020-11-10
SG10201706206PA (en) 2017-08-30
AU2014212509B2 (en) 2018-05-10
CY1119163T1 (el) 2018-02-14
SMT201700256T1 (it) 2017-09-07
RU2018126184A3 (es) 2021-07-26
AU2020204425A1 (en) 2020-07-23
PE20151781A1 (es) 2015-12-02
JP6389194B2 (ja) 2018-09-12
TW201443019A (zh) 2014-11-16
NZ750187A (en) 2020-09-25
RS61503B1 (sr) 2021-03-31
EP2953931B1 (en) 2017-03-01
SG11201505953TA (en) 2015-08-28
JP2016506963A (ja) 2016-03-07
DK3239134T3 (da) 2021-02-22
RU2662223C2 (ru) 2018-07-25
HUE033370T2 (en) 2017-11-28
US20180016235A1 (en) 2018-01-18
DK2953931T3 (en) 2017-06-06
WO2014120808A9 (en) 2015-05-14
AR094667A1 (es) 2015-08-19
EP3239134A1 (en) 2017-11-01
US20140213616A1 (en) 2014-07-31
US9393235B2 (en) 2016-07-19
HRP20170787T1 (hr) 2017-08-11
JP2021001232A (ja) 2021-01-07
PT3239134T (pt) 2021-01-28
LT3239134T (lt) 2021-02-25
HUE053448T2 (hu) 2021-06-28
US20170037009A1 (en) 2017-02-09
KR102227592B1 (ko) 2021-03-15
US10087143B2 (en) 2018-10-02
EP3865475A1 (en) 2021-08-18
GEAP201414909A (es) 2020-07-10
US20150246028A1 (en) 2015-09-03
WO2014120808A1 (en) 2014-08-07
EP2953931A1 (en) 2015-12-16
MX383688B (es) 2025-03-14
PH12015501661B1 (en) 2020-10-16
HRP20210349T1 (hr) 2021-04-16
IL240195B (en) 2019-10-31
PL2953931T3 (pl) 2017-09-29
US11673864B2 (en) 2023-06-13
IL269964B1 (en) 2025-09-01
WO2014120808A8 (en) 2015-09-11
ES2626555T3 (es) 2017-07-25
PT2953931T (pt) 2017-06-14
KR20210029848A (ko) 2021-03-16
CL2015002147A1 (es) 2016-06-03
PL3239134T3 (pl) 2021-06-14
SI3239134T1 (sl) 2021-03-31
KR20150112031A (ko) 2015-10-06
EP3239134B1 (en) 2020-12-23
GEP20217286B (en) 2021-08-25
AU2018214105B2 (en) 2020-04-02
SMT202100030T1 (it) 2021-03-15
AU2018214105B9 (en) 2020-04-23
AP2015008633A0 (en) 2015-07-31
CN105026373A (zh) 2015-11-04
AU2018214105A1 (en) 2018-08-30
HK1244269A1 (en) 2018-08-03
UA120589C2 (uk) 2020-01-10
HK1217693A1 (en) 2017-01-20
LT2953931T (lt) 2017-07-25
US20210047271A1 (en) 2021-02-18
CN105026373B (zh) 2018-03-30
KR102295748B1 (ko) 2021-09-01
AU2014212509A1 (en) 2015-08-06
CA2898866A1 (en) 2014-08-07
TW201943701A (zh) 2019-11-16
SI2953931T1 (sl) 2017-08-31
PH12015501661A1 (en) 2015-10-19
RU2018126184A (ru) 2019-03-12
CN108164457B (zh) 2021-07-09
MX2021003687A (es) 2023-01-25
ES2857687T3 (es) 2021-09-29
IL269964A (en) 2019-11-28
US20190248745A1 (en) 2019-08-15
US9051270B2 (en) 2015-06-09
IL240195A0 (en) 2015-09-24
CN108164457A (zh) 2018-06-15
CA2898866C (en) 2023-03-07
TWI655187B (zh) 2019-04-01
MX2015009602A (es) 2015-11-25
TWI714967B (zh) 2021-01-01
JP2018104453A (ja) 2018-07-05
JP6741704B2 (ja) 2020-08-19
JP2019089861A (ja) 2019-06-13
BR112015018289A2 (pt) 2017-07-18
US9758483B2 (en) 2017-09-12
NZ710270A (en) 2020-09-25
RU2015136795A (ru) 2017-03-10
UY35288A (es) 2014-08-29

Similar Documents

Publication Publication Date Title
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
ECSP16025201A (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio
MX359882B (es) Amidas como moduladores de canales de sodio.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
ES2620379T3 (es) Quinolina y quinoxalina amidas como moduladores de canales de sodio
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
UA109220C2 (uk) Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
PE20151651A1 (es) Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina
PE20121639A1 (es) Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
EA201592252A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
PE20141211A1 (es) Moduladores receptores de hormonas nucleares
WO2015100092A3 (en) 7-beta analogs of orvinols
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3